BioPharma Dive June 3, 2024
Lilly will pay the startup $45 million upfront for an RNA-based therapy in early development, and begin a research collaboration to unearth other, similar medicines.
Dive Brief:
- QurAlis, a Cambridge, Massachusetts-based biotechnology company developing drugs for neurodegenerative diseases, on Monday announced it has licensed an experimental medicine for ALS and frontotemporal dementia to Eli Lilly.
- Lilly will pay the startup $45 million upfront for rights to a therapy called QRL-204 and currently in preclinical development. Should the drug hit certain milestones, QurAlis could receive up to $577 million in additional payouts. The two will work together to develop other, similar medicines as well.
- Lilly has long made brain drugs a focus of its research, despite some high-profile setbacks and...
Today's Sponsors
Today's Sponsor